Issue Date: April 30, 2007
Cytos licenses vaccine to Novartis
Cytos Biotechnology has licensed CYT002-NicQb, a therapeutic vaccine in Phase II development for the treatment of nicotine addiction, to fellow Swiss firm Novartis. Cytos will get close to $30 million up front from Novartis and could receive almost $500 million in various milestone payments. According to Cytos, vaccination with CYT002-NicQb has been shown to induce nicotine-specific antibodies that bind nicotine in the bloodstream.
- Chemical & Engineering News
- ISSN 0009-2347
- Copyright © American Chemical Society